Myriad Genetics, Inc. (NASDAQ:MYGN) enjoyed a 31.06% run-up in share price since hitting record low of $26.05. The stock managed 5.01% rise and now stands at $34.14 as of 3/14/2019. At a recent session, the prices were hovering between $33.13 and $34.33. This company shares are 5.45% off its target price of $36 and the current market capitalization stands at $2.48B. The recent change has given its price a 15.24% lead over SMA 50 and -32.32% deficit over its 52-week high. The stock witnessed 11.86% gains, 10.88% gains and -25.93% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MYGN’s volatility during a week at 3.61% and during a month it has been found around 3.47%.Myriad Genetics, Inc. (MYGN) Top Holders
Institutional investors currently hold around $2.48 billion or 0% in MYGN stock. Look at its top three institutional owners: Blackrock Inc. owns $396.7 million in Myriad Genetics, Inc., which represents roughly 16% of the company’s market cap and approximately 16% of the institutional ownership. Similar statistics are true for the second largest owner, Baillie Gifford & Co, which owns 9,484,944 shares of the stock are valued at $308.36 million. The third largest holder is Vanguard Group Inc, which currently holds $298.86 million worth of this stock and that ownership represents nearly 12.05% of its market capitalization.Myriad Genetics, Inc. 13F Filings
At the end of December reporting period, 139 institutional holders increased their position in Myriad Genetics, Inc. (NASDAQ:MYGN) by some 8,015,704 shares, 126 decreased positions by 7,238,678 and 44 held positions by 61,035,528. That puts total institutional holdings at 76,289,910 shares, according to SEC filings. The stock grabbed 28 new institutional investments totaling 2,161,675 shares while 49 institutional investors sold out their entire positions totaling 1,073,001 shares.Myriad Genetics, Inc. (MYGN) Analyst Guide
Several analysts have released their opinion on Myriad Genetics, Inc. (NASDAQ:MYGN), with 3 analysts believing it is a strong buy. Whereas 4 of them predict the stock is a hold. Also, there are 2 buy, 3 sell and 0 strong sell ratings, collectively assigning a 2.58 average brokerage recommendation [T1].